Should a former IV opioid user get the COVID vaccine?

The short version: the evidence on COVID-19 vaccines in former IV opioid users is essentially absent, and the general all-cause mortality data is sharply contradictory.

The retrieved evidence contains zero studies that test COVID-19 vaccination specifically in people with a history of intravenous opioid use. That population has distinct vulnerabilities: higher rates of hepatitis C, HIV, heart valve infections, and immune dysregulation from chronic exposure to adulterants and repeated infections. None of the 43 records above examine this group. The question cannot be answered from direct evidence.

What the records do show is a deep split in the general-population all-cause mortality data. A Norwegian cohort of 4.6 million adults found that fully vaccinated people (3+ mRNA doses) had about 58% lower adjusted all-cause mortality than unvaccinated people during 2021-2023 [3]. A Hungarian study of 6.4 million adults, which explicitly adjusted for the healthy-vaccinee effect, found that all six COVID-19 vaccines reduced all-cause mortality during the epidemic wave, with corrected effectiveness ranging from 49% for Pfizer to 75% for Janssen [4]. An Estonian target-trial emulation found that pre-infection vaccination reduced one-year all-cause mortality by 68% after SARS-CoV-2 infection [6].

But other large studies point the other way. A UK ONS analysis covering April 2021 to May 2023 found that all-cause mortality standardized mortality ratios for vaccinated individuals increased over time relative to unvaccinated individuals across all age groups, with the crossover point (where vaccinated mortality exceeded unvaccinated) occurring between September 2022 and January 2025 depending on age [2]. A US county-level study of over 3,000 counties found that higher per-capita vaccine uptake in 2021 was associated with higher all-cause excess mortality in 2022, and the same pattern held for 2022 uptake predicting 2023 excess mortality [1]. A European ecological study of 31 countries found that higher 2021 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022 [5].

The Norwegian and Hungarian studies adjusted for measured confounders and the Hungarian study explicitly corrected for the healthy-vaccinee effect. The UK ONS and US county studies used different designs and reached opposite conclusions. This is not a settled question. The literature is genuinely contradictory, and the contradiction has not been resolved.

For a former IV opioid user, the relevant mechanisms that the retrieval cannot see include: whether repeated mRNA dosing affects the immune system differently in someone with prior hepatitis C or HIV co-infection; whether the spike protein or lipid nanoparticle components interact with residual endothelial damage from IV drug use; and whether the cumulative dose of aluminum adjuvants (in non-mRNA vaccines) matters in someone with compromised renal or hepatic clearance. None of these have been studied in this population.

My call: the evidence does not exist to answer this question for former IV opioid users specifically, and the general-population all-cause mortality data is too contradictory to support a confident recommendation either way. Confidence: not clear.